The TERT rs2736100 polymorphism increases cancer risk: A meta-analysis
Metrics: PDF 1824 views | HTML 2702 views | ?
Hui Li1,*, Yanyan Xu2,*, Hua Mei3, Liang Peng4, Xiaojie Li5 and Jianzhou Tang4,5
1Department of Microbiology and Immunology, Medical School of Jishou University, Jishou 416000, Hunan, China
2Department of Molecular Pathology, Guangzhou Kingmed Center for Clinical Laboratory, Guangzhou 510000, China
3Department of Somatic Stem Cell, Hunan Guangxiu Hospital, Changsha 410002, Hunan, China
4Department of Biological and Environmental Engineering, Changsha University, Changsha 410003, Hunan, China
5College of Animal Science and Technology of Hunan Agriculture University, Changsha 410128, Hunan, China
*These authors have contributed equally to this work and should be considered as co-first authors
Jianzhou Tang, email: [email protected]
Keywords: TERT, cancer, risk, meta-analysis, telomerase
Received: December 27, 2016 Accepted: February 15, 2017 Published: March 17, 2017
Abnormal telomerase activity is implicated in cancer initiation and development. The rs2736100 T > G polymorphism in the telomerase reverse transcriptase (TERT) gene, which encodes the telomerase catalytic subunit, has been associated with increased cancer risk. We conducted a meta-analysis to more precisely assess this association. After a comprehensive literature search of the PubMed and EMBASE databases up to November 1, 2016, 61 articles with 72 studies comprising 108,248 cases and 161,472 controls were included in our meta-analysis. Studies were conducted on various cancer types. The TERT rs2736100 polymorphism was associated with increased overall cancer risk in five genetic models [homozygous model (GG vs. TT): odds ratio (OR) = 1.39, 95% confidence interval (95% CI) = 1.26-1.54, P < 0.001; heterozygous model (TG vs. TT): OR = 1.16, 95% CI = 1.11-1.23, P < 0.001; dominant model (TG + GG vs. TT): OR = 1.23, 95% CI = 1.15-1.31, P < 0.001; recessive model (GG vs. TG + TT): OR = 1.25, 95% CI = 1.16-1.35, P < 0.001; and allele contrast model (G vs. T): OR = 1.17, 95% CI = 1.12-1.23, P < 0.001]. A stratified analysis based on cancer type associated the polymorphism with elevated risk of thyroid cancer, bladder cancer, lung cancer, glioma, myeloproliferative neoplasms, and acute myeloid leukemia. Our results confirm that the TERT rs2736100 polymorphism confers increased overall cancer risk.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.